| Title: |
Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017–2022: An Analysis of the International Severe Asthma Registry |
| Authors: |
Le, Tham T.; Price, David B.; Erhard, Clement; Cook, Bill; Quinton, Anna; Katial, Rohit; Christoff, George C.; Perez-De-llano, Luis; Altraja, Alan; Bergeron, Celine; Bourdin, Arnaud; Koh, Mariko Siyue; Lehtimäki, Lauri; Mahboub, Bassam; Papadopoulos, Nikolaos G.; Pfeffer, Paul; Rhee, Chin Kook; Carter, Victoria; Martin, Neil; Tran, Trung N. |
| Contributors: |
Tampere University; KIHA, Keuhko-, iho- ja allergiasairaudet; KIHA, Pulmonology, dermatology, and allergology |
| Publication Year: |
2024 |
| Time: |
3121 |
| Description: |
Introduction: Patients with severe asthma may be prescribed biologic therapies to improve disease control. The EVEREST study aimed to characterize the global disease burden of patients with severe asthma without access to biologics and those who have access but do not receive biologics, as well as the remaining unmet need despite use of these therapies. Methods: This was a historical cohort study of patients with severe asthma (aged ≥18 years) in the International Severe Asthma Registry receiving Global Initiative for Asthma (GINA) 2018 step 5 treatment, or with uncontrolled disease at GINA step 4. Prospective data on patient clinical characteristics, healthcare resource utilization, and medication use over a 12-month period between December 2017 and May 2022 were assessed for the following five groups: biologics accessible (omalizumab, mepolizumab, reslizumab, benralizumab, or dupilumab); biologics inaccessible; biologics accessible but not received; biologics accessible and received; and biologic recipients whose asthma remained suboptimally controlled. Results: Overall, 9587 patients from 21 countries were included. Among patients in the biologics accessible (n=5073), biologics inaccessible (n=3041), and biologics accessible but not received (n=382) groups, 41.4%, 18.7%, and 49.6% experienced at least two exacerbations, 11.5%, 10.5%, and 6.2% required at least one hospitalization, 47.9%, 54.6%, and 71.2% had uncontrolled asthma, and 23.9%, 8.6%, and 11.0% received long-term oral corticosteroids (LTOCS), respectively. Following biologic therapy, among patients who received biologics overall (n=2666) and among those whose asthma remained suboptimally controlled (n=1780), 19.1% and 23.0% experienced at least two exacerbations, 2.7% and 2.9% required at least one hospitalization, and 16.7% and 22.0% received LTOCS, respectively. Conclusion: There is a substantial disease burden in both patients without access to biologics and those with access who do not receive these therapies, although specific outcomes may ... |
| Document Type: |
article in journal/newspaper |
| File Description: |
1055-1069; fulltext |
| Language: |
English |
| Relation: |
Journal of Asthma and Allergy; 17; https://trepo.tuni.fi/handle/10024/210946 |
| DOI: |
10.2147/JAA.S468068 |
| Availability: |
https://trepo.tuni.fi/handle/10024/210946; https://doi.org/10.2147/JAA.S468068 |
| Rights: |
cc by-nc 4.0 ; openAccess |
| Accession Number: |
edsbas.FBE0E9FC |
| Database: |
BASE |